In Vitro Efficacy of Known P-Glycoprotein Modulators Compared to Droloxifene E and Z: Studies on a Human T-Cell Leukemia Cell Line and their Resistant Variants

References

• Biedler J.L., Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro, cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970; 30: 1174–1184
   PubMed Web of Science ®Google Scholar
• Arceci R.J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215
   PubMed Web of Science ®Google Scholar
• Lum B.L., Fisher G.A., Brophy N.A., Yahanda A.M., Adler K.M., Kaubisch S., Halsey J., Sikic B.I. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 1993; 72: 3502–3514
   PubMed Web of Science ®Google Scholar
• Raderer M., Scheithauer W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 1993; 72: 3553–3563
   PubMed Web of Science ®Google Scholar
• Goldstein L.J. Clinical reversal of drug resistance. Curr Probl Cancer 1995; 19: 65–124
   PubMedGoogle Scholar
• Leveque D., Jehl F. P-glycoprotein and pharmacokinetics. Anticancer Res 1995; 15: 331–336
   PubMed Web of Science ®Google Scholar
• Hasmann M., Rattel B., Löser R. Preclinical data for Droloxifene. Cancer Letters 1994; 84: 101–116
   PubMed Web of Science ®Google Scholar
• Löser R., Seibel K., Huber H.J. Pharmacological activities of Droloxifene isomers. Anticancer Res 1988; 8: 1271–1274
   PubMed Web of Science ®Google Scholar
• Leonessa F., Jacobson M., Boyle B., Lippman J., McGarvey M, Clarke R. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells, isobologram, drug accumulation, and M(r) 170,000 plycoprotein (gp170) binding studies. Cancer Res 1994; 54: 441–447
   PubMed Web of Science ®Google Scholar
• Hofmann J., Gekeler V., Ise W., Noller A., Mitterdorfer J., Hofer S., Utz I., Gotwald M., Boer R., Glossmann H., et al. Mechanism of action of dexniguldipine-HCI (B8509-035), a new potent modulator of multidrug resistance. Biochem-Pharmacol 1995; 49(5): 603–9
   Web of Science ®Google Scholar
• Neumann M., Wilisch A., Diddens H., Probst H., Gekeler V. MDR hamster cells exhibiting multiple altered gene expression, effects of dexniguldipine-HCI (B859-35), cyclosporin A and buthionine sulfoximine. Anticancer Res 1992; 12: 2297–2302
   PubMed Web of Science ®Google Scholar
• Hŝsllt V., Kouba M., Dietel M., Vogt G. Stereoisomeres of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem-Pharmacol. 1992; 43: 2601–2608
   PubMed Web of Science ®Google Scholar
• Boer R., Ulrich W.R., Haas S., Borchers C., Gekeler V., Boss H., Przybylski M., Schodl A. Interaction of cytostatics and chemosensitizers with the dexniguldipine binding site on P-glycoprotein. Eur J Pharmacol 1996; 295: 253–260
   PubMed Web of Science ®Google Scholar
• Ferry D.R., Malkhandi P.J., Russell M.A., Kerr D.J. Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem-Pharmacol 1995; 49(12): 1851–61
   Web of Science ®Google Scholar
• Malkhandi J., Ferry D.R., Boer R., Gekeler V., Ise W., Kerr D.J. Dexniguldipine-HCI is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells. Eur J Pharmacol 1994; 288: 105–114
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Michelutti A., Candoni A., Masolini P., Scaggiante B., Quadriofoglio F., Baccarani M. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833. Haematologica 1994; 79: 500–7
   PubMed Web of Science ®Google Scholar
• Arceci R., Stieglitz K., Bras J., et al. Monoclonal antibody to an external epitope of the human mdrl P-glycoprotein. Cancer Res 1993; 53: 310–317
   PubMed Web of Science ®Google Scholar
• Maslak P., Hegewisch-Becker S., Godfrey L, et al. Flow cytometric determination of the multidrug resistant phenotype in acute leukemia. Cytometry 1994; 17: 84–93
   PubMedGoogle Scholar
• Young I.T. Proof without prejudice: use of the Kolmogorov Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 1977; 25: 935–941
   PubMed Web of Science ®Google Scholar
• Nüssler V., Gullis E., Pelka-Fleischer R., del Valle E., Diem H., Beyerlein S., Zwierzina H., Wilmanns W. Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients. Ann Hematol 1997; 75: 17–26
   PubMed Web of Science ®Google Scholar
• Cole S.P.C., Sparks K.E, Fraser K., et al. Pharmacological Characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902–5910
   PubMed Web of Science ®Google Scholar
• Scheper J.R., Broxterman H.J., Scheffer G.L., et al. Overexpression of a M 110, 000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53: 1475–1479
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetrie assay for cellular growth and survival, application to proliferation in cytotoxicity assays. J Immunol Methods 1981; 65: 55–63
   Web of Science ®Google Scholar
• Carmichael J., Degraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetrie assay, assessment of chemosensitivity testing. Cancer Res 1987; 47: 936–942
   PubMed Web of Science ®Google Scholar
• Scheffer G.L., Wijngaard P.L.J., Flens M.J., et al. The drug resistance-related protein LRP is the human major vault protein. Nature Med 1995; 1: 578–582
   PubMed Web of Science ®Google Scholar
• Nuessler V., Scheulen M.E., Oberneder R., Kriegmair M., Rathgeb F., Wurst W., Zech K., Wilmanns W. Phase 1 and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCI. Eur J Med Res 1996; 2: 55–61
   Google Scholar
• Tsuruo T., Tomida A. Multidrug resistance. Anticancer Drugs 1995; 6: 213–218
   PubMed Web of Science ®Google Scholar
• Kerr D.J., Graham J., Cummings J., Morrison J.G., Thompson G.G., Brodie M.J., Kaye S.B. The effect of Verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986; 18: 239–242
   PubMed Web of Science ®Google Scholar
• Mross K., Hamm K., Hossfeld D.K. Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. Cancer Chemother Parmacol 1993; 31: 369–375
   PubMed Web of Science ®Google Scholar
• Lum B.L., Kaubisch S., Yahanda A.M., Adler K.M., Jew L., Ehsan M.N., Brophy N.A., Halsey J., Gosland M.P., Sikie B.I. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635–1642
   PubMed Web of Science ®Google Scholar
• Erlichman C., Morre M., Thiessen J.J., Kerr I.G., Walker S., Goodman P., Bjarnason G., DeAngelis C., Bunting P. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 1993; 53: 4837–4842
   PubMed Web of Science ®Google Scholar
• Christen R.D., McClay E.F., Plaxe S.C., Yen S. S. C. V., Kim S., Kirmani S., Wilgus L.L., Heath D.D., Shalinsky D.R., Freddo J.L., Braly P.S., O'Quigley J., Howell S.B. Phase I/Pharmacolinetic study of high-dose progesterone and doxorubicin. J Clin Oncol 1993; 11: 2417–2426
   PubMed Web of Science ®Google Scholar
• Berman E., McBride M., Lin S., Mendez-Botet C., Tong W. Phase 1 trail of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed of refractory acute leukemia. Leukemia 1995; 9: 1631–1637
   PubMed Web of Science ®Google Scholar
• Chatterjee M., Harris A.L. Reversal of acquired resistance to adriamycin in CHO cells by tamoxifen and 4-hydroxy tamoxifen, role of drug interaction with alpha 1 acid glycoprotein. Br J Cancer 1990; 62: 712–7
   PubMed Web of Science ®Google Scholar
• Zhang J.J., Jacob T.J., Valverde M.A., Hardy S.P., Mintenig G.M., Sepulveda F.V., Gill D.R., Hyde S.C., Trezise A.E., Higgins C.F. Tamoxifen blocks chloride channel. A possible mechanism for cataract formation. J. Clin Invest 1994; 94: 1690–1697
   Google Scholar